Wright Gerard D, Sutherland Arlene D
Antimicrobial Research Centre, Department of Biochemistry and Biomedical Sciences, DeGroote School of Medicine, McMaster University, 1200 Main St W, Hamilton, Ontario, L8N 3Z5, Canada.
Trends Mol Med. 2007 Jun;13(6):260-7. doi: 10.1016/j.molmed.2007.04.004. Epub 2007 May 9.
Antibiotic resistance is a problem that continues to challenge the healthcare sector. In particular, multidrug resistance is now common in familiar pathogens such as Staphylococcus aureus and Mycobacterium tuberculosis, as well as emerging pathogens such as Acinetobacter baumannii. New antibiotics and new therapeutic strategies are needed to address this challenge. Advances in identifying new sources of antibiotic natural products and expanding antibiotic chemical diversity are providing chemical leads for new drugs. Inhibitors of resistance mechanisms and microbial virulence are orthogonal strategies that are also generating new chemicals that can extend the life of existing antibiotics. This new chemistry, coupled with a growing understanding of the mechanisms, origins and distribution of antibiotic resistance, position us to tackle the challenges of antibiotic resistance in the 21st century.
抗生素耐药性是一个持续挑战医疗保健领域的问题。特别是，多重耐药性目前在常见病原体如金黄色葡萄球菌和结核分枝杆菌中很常见，在鲍曼不动杆菌等新兴病原体中也很常见。需要新的抗生素和新的治疗策略来应对这一挑战。在确定抗生素天然产物的新来源和扩大抗生素化学多样性方面取得的进展正在为新药提供化学线索。耐药机制和微生物毒力的抑制剂是正交策略，也正在产生能够延长现有抗生素使用寿命的新化学物质。这种新化学物质，再加上对抗生素耐药性的机制、起源和分布的日益了解，使我们有能力应对21世纪抗生素耐药性的挑战。
